Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Details for Australian Patent Application No. 2005300727 (hide)

Owner Switch Biotech LLC

Inventors Bell, Stefan

Agent Pizzeys

Pub. Number AU-B-2005300727

PCT Pub. Number WO2006/048242

Priority 04025961.6 02.11.04 EP

Filing date 2 November 2005

Wipo publication date 11 May 2006

Acceptance publication date 15 July 2010

International Classifications

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/06 (2006.01) Drugs for dermatological disorders

Event Publications

3 May 2007 PCT application entered the National Phase

  PCT publication WO2006/048242 Priority application(s): WO2006/048242

2 April 2009 Assignment before Grant

  Switch Biotech AG The application has been assigned to Switch Biotech LLC

15 July 2010 Application Accepted

  Published as AU-B-2005300727

11 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005300731-Multi-component dressing for wound treatment on the human or animal body with application of reduced pressure

2005300725-Device for the treatment of wounds using a vacuum